Our work is aimed at unraveling the role of the first-phase insulin secretion in the natural
history of type 2 diabetes mellitus (T2DM) and its interrelationship with insulin resistance …

Introduction In clinical trials, liraglutide has proven to be an effective drug for the treatment of
type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been …

Aim To investigate the effects of semaglutide on fasting and postprandial glucose and lipid
responses, and on gastric emptying. Materials and methods This was a randomized, double …

Aims/hypothesis Semaglutide is a glucagon-like peptide-1 analogue in development for the
treatment of type 2 diabetes. Its effects on first-and second-phase insulin secretion and other …

Background Several clinical trials have studied the effects of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycometabolism and cardiovascular risk factors since …

Background The prevalence of type 2 diabetes in youth is escalating rapidly. We aimed to
evaluate the effects of liraglutide on beta-cell function, metabolic productions of oxidative …

The loss of beta-cell functional mass is a necessary and early condition in the development
of type 2 diabetes (T2D). In T2D patients, beta-cell function is already reduced by about 50 …

Abstract Aims/Introduction Liraglutide and empagliflozin suppress cardiovascular events.
However, reports on their long‐term combined use with insulin therapy or direct …

Introduction Despite the widespread use of glucagon-like peptide-1 (GLP-1) receptor
agonists (GLP-1ras) to improve glycemic regulation, with a low risk of hypoglycemia and …

Aims This randomized, open-label, parallel-group, controlled trial compared the effects of
dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes. Materials …